이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Study of the Effects of Rimonabant on Functional Recovery in Subacute Stroke Patients (RIMOSTROKE-2)

2026년 11월 16일 업데이트: Sinfatin S.L

Effects of a CB1 Antagonist/Inverse Agonist (Rimonabant) on Functional Recovery in Stroke Patients During Subacute Phase (RIMOSTROKE-2)

The main goal of this clinical trial is to assess the effect of rimonabantim on the functional independence in adults who have recently experienced a stroke. The study will enroll 80 participants aged 18 to 75 years who had an stroke 30 to 90 days before enrolment and who have difficulties performing daily activities.

Participants will receive either rimonabant (5 mg) or placebo (a look-alike tablet that contains no drug) once daily for 90 days. Neither the participants nor the investigators will know which treatment is being given.The study will also help to learn about the safety of rimonabant.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

Stroke is a major cause of disability worldwide. Many patients experience persistent functional limitations that can affect their independence in daily activities and quality of life, despite being involved in rehabilitation programs.

The endocannabinoid system, particularly the cannabinoid type 1 (CB1) receptor, is involved in the regulation of neuronal activity and motor function. Rimonabant is a selective CB1 receptor antagonist/inverse agonist that has demonstrated effects on corticospinal excitability and motor performance in previous preclinical and clinical research.

Based on this evidence, this study aims to investigate whether treatment with low-dose rimonabant can improve functional independence in post-stroke patients during the subacute phase. RIMOSTROKE-2 is a multicenter, randomized, double-blind, placebo-controlled Phase IIb clinical trial, to evaluate efficacy and safety of rimonabant.

The primary objective is to evaluate the effect of rimonabant on functional independence, measured by the change in the total Barthel Index (BI) score. Secondary objectives include assessing motor function, walking ability, balance, fatigue, neurological status, cognitive function and health-related quality of life. The safety and tolerability of rimonabant will also be evaluated through adverse event monitoring, clinical examinations, laboratory tests, vital signs and electrocardiogram.

The treatment period will last 90 days, followed by a 45-day follow-up period. All participants will continue to receive standard medical care and rehabilitation.

연구 유형

중재적

등록 (추정된)

80

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

    • Albacete
      • Albacete, Albacete, 스페인, 02006
        • Hospital Universitario de Albacete
        • 연락하다:
    • Barcelona
      • Badalona, Barcelona, 스페인, 08916
        • Institut Guttmann
        • 연락하다:
    • Córdoba
      • Córdoba, Córdoba, 스페인, 14004
        • Jiménez Lucena S.L. (CLÍNICA I+TÚ)
        • 연락하다:
    • Madrid
      • Brunete, Madrid, 스페인, 28690
        • Hospital Los Madroños
        • 연락하다:
      • Madrid, Madrid, 스페인, 28046
      • Madrid, Madrid, 스페인, 28040
        • Hospital Clínico San Carlos (HCSC)
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Age between 18 and 75 years.
  • Between 30 days and 3 months (30 - 90 days) since the stroke.
  • mRS score between 2 and 4.
  • BI score ≤ 70 at screening.
  • Capacity to provide informed consent.

Exclusion Criteria:

  • High suicide risk assessed by C-SSRS.
  • History of severe psychiatric disorders, major depression or prior suicide attempts.
  • Treatment with anticoagulants or strong CYP3A4 inhibitors or inducers (inhibitors such as ketoconazole, itraconazole, ritonavir, telithromycin, clarithromycin, or nefazodone, and inducers such as rifampicin, phenytoin, phenobarbital, carbamazepine, or St. John's Wort).
  • Patients with a history of ischemic or haemorrhagic stroke resulting in a residual mRS > 1, or with a pre-existing mRS > 1 due to other medical conditions.
  • BMI > 40 kg/m².
  • Pregnancy or breastfeeding.
  • Fertile men or women who cannot guarantee the use of highly effective contraceptive methods, as defined by the European HMA-CTFG guidelines at least 45 days after the last dose of rimonabant -i.e., those with a failure rate of less than 1 % per year when used consistently and correctly (CTFG, 2020).
  • Uncontrolled hypothyroidism, or a history of severe bone, liver, or kidney disease.
  • Known allergy to rimonabant or any of the excipients used.
  • Participation in another clinical trial within the month prior to enrolment.
  • Any other condition that, in the opinion of the investigator, makes the subject's participation in the study unrecommended, such as severe heart failure or uncontrolled diabetes.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Rimonabant 5 mg

Participants randomized to receive rimonabant 5 mg.

Rimonabant 5 mg administered orally as one orally disintegrating tablet (ODT) once daily for 90 consecutive days.

위약 비교기: Placebo

Participants randomized to receive matching placebo.

Participants will receive one matching placebo orally disintegrating tablet (ODT) once daily for 90 consecutive days. The placebo contains no rimonabant.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Barthel Index (BI)
기간: Baseline and end of follow-up (day 135)

The BI measures the ability to perform activities of daily living. It consists on a ten-item scale that examine functions such as feeding, bathing, continence, mobility and dressing.

Baseline and end of follow-up (day 135)

2차 결과 측정

결과 측정
측정값 설명
기간
Five-level EuroQol five-dimension questionnaire (EQ-5D-5L)
기간: Baseline and end of follow-up (day 135)

The EQ-5D-5L assesses health-related quality of life across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Responses are converted into a health utility index using an appropriate value set.

Baseline and end of follow-up (day 135)
Adverse Events (AEs)
기간: Baseline and end of follow-up (day 135)

Number of participants experiencing at least one adverse event (AE). Adverse events will be recorded and assessed by severity, causality, and type.

Baseline and end of follow-up (day 135)
Serious Adverse Events (SAEs)
기간: Baseline and end of follow-up (day 135)

Number of participants experiencing at least one serious adverse event (SAE) during the study.

Baseline and end of follow-up (day 135)
Adverse Events of Special Interest (AESIs)
기간: Baseline and end of follow-up (day 135)

Number of participants experiencing at least one protocol-defined adverse event of special interest. Particular attention is given to psychiatric events and clinically relevant changes in mental status because of the known psychiatric risk profile of rimonabant.

Baseline and end of follow-up (day 135)
Beck Depression Inventory-II (BDI-II)
기간: Baseline and end of follow-up (day 135)

The Beck Depression Inventory-II (BDI-II) assesses depressive symptoms. Higher scores indicate greater depressive symptom severity. According to the protocol, a score ≥20 triggers clinical evaluation by the investigator.

Baseline and end of follow-up (day 135)
The Visual Analogue Scale for Pain (VAS-P)
기간: Baseline and end of follow-up (day 135)

Assesses the participant's subjective perception of pain intensity. Changes from baseline will be used to identify clinically significant changes in pain during treatment and follow-up.

Baseline and end of follow-up (day 135)
Spasticity Assessed by Modified Ashworth Scale (MAS)
기간: Baseline and end of follow-up (day 135)

The MAS assesses resistance to passive movement as a measure of muscle spasticity. Scores range from 0 (no increase in muscle tone) to 4 (affected part rigid in flexion or extension), including an intermediate category of 1+. Higher scores indicate greater spasticity.

Baseline and end of follow-up (day 135)
Number of Falls
기간: Baseline and end of follow-up (day 135)

Mean number of falls during the previous 30 days, based on weekly records in the participant diary and collected at each follow-up visit.

Baseline and end of follow-up (day 135)
Six-Minute Walk Test (6MWT)
기간: Baseline and end of follow-up (day 135)

The 6MWT assesses walking capacity by measuring the distance walked in six minutes, expressed in meters. The primary endpoint is the percentage change in walking distance from baseline to the end of follow-up on day 135. Greater distances indicate better walking capacity.

Baseline and end of follow-up (day 135)
Ten-Meter Walk Test (10MWT)
기간: Baseline and end of follow-up (day 135)

The Ten-Meter Walk Test (10MWT) assesses walking performance by measuring the time required to walk 10 meters at a comfortable or maximal pace. Shorter completion times indicate faster walking performance. Walking speed over 10 meters is reported in meters/second.

Baseline and end of follow-up (day 135)
Borg CR10 Scale
기간: Baseline and end of follow-up (day 135)

The Borg CR10 Scale assesses perceived exertion after the 6MWT. Scores range from 0 (no exertion) to 10 (maximal exertion). Higher scores indicate greater perceived exertion.

Baseline and end of follow-up (day 135)
Fatigue Severity Scale (FSS)
기간: Baseline and end of follow-up (day 135)

The FSS assesses the impact of fatigue on daily functioning. It contains nine items scored from 1 to 7. The mean score is calculated, with higher scores indicating greater fatigue severity.

Baseline and end of follow-up (day 135)
Stroke Impact Scale (SIS 3.0)
기간: Baseline and end of follow-up (day 135)

The SIS 3.0 assesses the impact of stroke on health and daily functioning across multiple domains. Domain scores range from 0 to 100, with higher scores indicating better functioning or fewer limitations.

Baseline and end of follow-up (day 135)
Patient Global Impression of Change (PGIC)
기간: End of treatment (day 90) and End of follow-up (day 135)

The PGIC assesses the participant's overall perception of change in their condition. Scores range from 1 (very much improved) to 7 (very much worse), with 4 indicating no change.

End of treatment (day 90) and End of follow-up (day 135)
Hospital Anxiety and Depression Scale-Anxiety (HADS-A)
기간: Baseline and end of follow-up (day 135)

The anxiety subscale of the Hospital Anxiety and Depression Scale (HADS) assesses anxiety symptoms. Higher scores indicate greater symptom severity. A score ≥11 triggers clinical evaluation by the investigator.

Baseline and end of follow-up (day 135)
Hospital Anxiety and Depression Scale-Depression (HADS-D)
기간: Baseline and end of follow-up (day 135)

The depression subscale of the Hospital Anxiety and Depression Scale (HADS) assesses depresive symptoms. Higher scores indicate greater symptom severity. A score ≥11 triggers clinical evaluation by the investigator.

Baseline and end of follow-up (day 135)
Timed Up and Go test (TUG)
기간: Baseline and end of follow-up (day 135)

The TUG assesses functional mobility and fall risk by measuring the time taken to stand up from a chair, walk 3 meters, turn around, return and sit down. Longer times indicate poorer functional mobility and a higher risk of falls.

Baseline and end of follow-up (day 135)
Berg Balance Scale (BBS)
기간: Baseline and end of follow-up (day 135)

The BBS assesses static and dynamic balance through 14 functional tasks, providing a quantitative measure of postural control and fall risk. Higher scores indicate better balance and a lower risk of falls.

Baseline and end of follow-up (day 135)
Fugl-Meyer Assessment - Upper Extremities (FMA-UE)
기간: Baseline and end of follow-up (day 135)

The FMA-UE assesses upper limb motor function after stroke, evaluating movement control, coordination and reflex activity. Higher scores indicate better motor function and less severe upper limb impairment.

Baseline and end of follow-up (day 135)
National Institutes of Health Stroke Scale (NIHSS)
기간: Baseline and end of follow-up (day 135)

The NIHSS assesses the severity of neurological deficits after stroke by evaluating consciousness, language, motor, sensory and visual functions. Scores range from 0 to 42, with higher scores indicating greater neurological impairment and more severe stroke symptoms.

Baseline and end of follow-up (day 135)
Modified Rankin Scale (mRS)
기간: Baseline and end of follow-up (day 135)

The mRS assesses the degree of global disability and dependence in activities of daily living (ADL) following a neurological event. Scores range from 0 (no symptoms) to 6 (death), with higher scores indicating greater disability and dependence.

Baseline and end of follow-up (day 135)
Montreal Cognitive Assessment (MoCA)
기간: Baseline and end of follow-up (day 135)

The MoCA assesses global cognitive function through the evaluation of attention, memory, executive functions, language, visuospatial abilities and orientation. Scores range from 0 to 30, with higher scores indicating better cognitive performance.

Baseline and end of follow-up (day 135)
Swallowing Disturbance Questionnaire (SDQ)
기간: Baseline and end of follow-up (day 135)

The SDQ assesses the presence and severity of swallowing disorders through a self-reported questionnaire, identifying symptoms associated with dysphagia. Higher scores indicate more severe swallowing difficulties and a greater likelihood of dysphagia.

Baseline and end of follow-up (day 135)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 11월 30일

기본 완료 (추정된)

2028년 1월 31일

연구 완료 (추정된)

2028년 12월 31일

연구 등록 날짜

최초 제출

2026년 11월 11일

QC 기준을 충족하는 최초 제출

2026년 11월 16일

처음 게시됨 (실제)

2026년 11월 17일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 17일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 16일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • RIMOSTROKE-2
  • 2025 (미국 NIH 보조금/계약)
  • 2025-521689-86-00 (씨티스)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .